Clinical Trial Update: Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating whether circulating tumor DNA can guide an early switch from first-line mFOLFIRINOX in metastatic pancreatic ductal adenocar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• modified FOLFIRINOX (mFOLFIRINOX)

Snippet

Sponsor: University of Miami | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: RECRUITING